Article Text
PDF
Abstract
Background and aims Treatment of alcohol withdrawal syndrome (AWS) is challenging, especially in those with alcohol-related liver disease (ArLD). Guidelines suggest using shorter-acting benzodiazepines (BZDs) but clinical evidence is sparse. We assessed the management of AWS using the Glasgow Modified Alcohol Withdrawal Scale (GMAWS), with a symptom-triggered treatment (STT) approach using lorazepam in ArLD patients.
Method Three groups of patients were identified: group 1: patients without ArLD with AWS; group 2: ArLD patients with AWS and group 3: ArLD patients without AWS. BZD use in the first 48 hours of admission was calculated, and alcohol use disorder was assessed with the Fast Alcohol Screening Tool (FAST).
Results Of 613 hospital episodes, 232 were in group 1, 174 in group 2 and 207 in group 3. Compared with group 1, group 2 patients had lower FAST scores (14 (13, 15) cf 15 (14, 16); p=0.036), initial GMAWS (0 (0, 0) cf 2 (1, 2); p<0.0001) and less BZD prescribed (30 (20, 42) cf 30 (20, 42) mg; p<0.0001). STT (83% cf 48%: p<0.0001) and lorazepam (79% cf 22%: p<0.0001) were more common in group 2 patients. AWS treatment was not associated with a worse 180-day survival in ArLD patients (91.3% in group 2 and 80.2% in group 3).
Conclusion Patients managed for AWS without ArLD received greater amounts of BZDs compared with those with both AWS and ArLD. There was no evidence of a survival disadvantage for those with ArLD managed for AWS. An STT approach favouring lorazepam for the management of AWS in ArLD was effective using the GMAWS guidance.
- ALCOHOL
- CIRRHOSIS
- ALCOHOLIC LIVER DISEASE
Data availability statement
Data are available upon reasonable request.
Statistics from Altmetric.com
Data availability statement
Data are available upon reasonable request.
Footnotes
X @EwanForrest1
Contributors Study concept and design: EHF; analysis and interpretation of data: EHF, LI, SH, GS and AD; drafting of the manuscript: EHF; critical revision of the manuscript for important intellectual content: EHF, LI, SH, GS and AD. Professor EHF is the guarantor of the article. All authors approved the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.